|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
|
Fig. 5. Actomyosin disruption inhibits CME. (A) T cells were pre-treated with Y-27632 (20 µM, 2 hours), blebbistatin (30 µM, 20 minutes), cytochalasin D (2.5 µg/ml, 2 hours), latrunculin B (0.6 µg/ml, 5 minutes) or colchicine (1 µg/ml, 2 hours) were evaluated for Tfn uptake for 5 and 10 minutes. For the rescue assays the Tfn uptake was re-evaluated after a 5-10 minute wash in fresh medium (n=50 cells for each condition). Similarly, C3-GFP- and the dominant-negative RhoAN19-GFP-transfected cells were evaluated for Tfn uptake for 5 and 10 min (n=10 cells for each condition). The internal pool of Tfn was evaluated as described in Materials and Methods and supplementary material Fig. S3. Values are compared with the control. (B) T cells plated on ICAM-1 were checked for Tfn internalization (10 minute pulse of Tfn-A488, or Tfn-A633 in C3-GFP-transfected cell) and surface TfnR distribution in control, C3-GFP-transfected cells (pseudo-colored in cyan), and pre-treated with Y-27632 and blebbistatin as in A. Bar, 5 µm.
|
